The accumulation of specific phosphorylated protein aggregates in the brain is a hallmark of severe neurodegenerative disorders. Specifically, hyperphosphorylated tau (hp-tau) accumulates in Alzheimer disease, frontotemporal dementia with Parkinsonism linked to chromosome 17, and progressive supranuclear palsy; furthermore, phosphorylated a-synuclein (p-aSyn) accumulates in Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Moreover, codeposition of different pathological protein aggregates is common in the brains of individuals with neurodegenerative diseases. In the present report, we describe the detection of p-aSyn aggregates in the brain of rTg4510 mice that overexpress human P301L mutant tau. Immunohistochemistry showed that hptau and p-aSyn aggregates were found within the same neuronal cells in rTg4510 mice and increased with age. Moreover, semiquantitative analysis revealed a significant regional correlation between hp-tau and p-aSyn accumulation. These results indicate that endogenous mouse aSyn protein is phosphorylated and accumulates with hp-tau aggregation in neurons and suggest that the overexpression of human P301L mutant tau may enhance endogenous aSyn phosphorylation and aggregation via a similar hyperphosphorylation mechanism in vivo. This synergic effect between tau and aSyn accumulation may exacerbate the pathology of several neurodegenerative disorders that show a cooccurrence of hp-tau and p-aSyn aggregation.
INTRODUCTION
Neurodegenerative disorders are characterized by the accumulation of abnormal protein aggregates and neuronal loss in the central nervous system and are classified into 3 categories according to the proteins accumulated. Intracytoplasmic hyperphosphorylated tau (hp-tau) aggregates are pathognomonic in tauopathies such as Alzheimer disease (AD), frontotemporal dementia with Parkinsonism linked to chromosome 17, and progressive supranuclear palsy (PSP) (1), while phosphorylated a-synuclein (p-aSyn) aggregates are involved in a-synucleinopathies such as Parkinson disease (PD), dementia with Lewy bodies (DLBs), and multiple system atrophy (MSA) (2) . Phosphorylated transactivation response DNA protein 43 (TDP-43) aggregates play a causative role in TDP-43 proteinopathies such as frontotemporal lobar degeneration and amyotrophic lateral sclerosis (3) .
Both tau and aSyn are natively unfolded soluble proteins that are minimally phosphorylated in the normal adult brain. However, in pathological states they undergo conformational changes such as phosphorylation, which subsequently leads to oligomerization. Additionally, they can become ubiquitinated and form intracytoplasmic insoluble filamentous aggregates (4) (5) (6) (7) . In AD, tau proteins are phosphorylated at the serine (S) 199, 202, and 396, and threonine 205 positions and form ultrastructural paired helical filaments, resulting in neurofibrillary tangles (1) . In a-synucleinopathies such as PD, DLB, and MSA, 90% of aSyn molecules are phosphorylated at the S129 position and form intracytoplasmic inclusions called Lewy bodies (LBs) (8) . The spread of phosphorylated tau and aSyn accumulation is closely correlated with disease progression; therefore, the distribution and spread of phosphorylated tau and aSyn are useful for determining disease stage in sporadic AD and PD, respectively (4, 9) . Recent studies have proposed a "seeding" hypothesis, in which small amounts of misfolded proteins act as seeds that initiate the recruitment of their soluble counterparts into fibrils and the cellto-cell transmission of protein aggregates (4, 10) .
The simultaneous accumulation of different proteins in the diseased brain is a common feature in many neurodegenerative diseases (11) (12) (13) (14) . Some reports have indicated that intracellular p-aSyn aggregates, together with hp-tau accumulation, are frequently found in tauopathies such as AD (15) (16) (17) , PSP (18, 19) , and FTD (20, 21) . Studies using antibodies against aSyn have demonstrated that LBs are detected in the amygdala of over 60% of familial and sporadic AD cases (22, 23) . Conversely, hp-tau aggregates have been observed in over 50% of a-synucleinopathy cases, including cases of PD, DLB, and MSA (24) . Clinical and postmortem observations have revealed that cases of AD with LBs are associated with faster and more severe cognitive decline as well as accelerated mortality than AD cases without LBs (14, 25, 26) . It has also been suggested that the filamentous aggregates composed of 1 protein (tau or aSyn) in the brain may directly promote the aggregation of the other protein through a process called "cross-seeding" (11, 27) . The results of in vitro analyses have revealed that coincubation of tau with aSyn, even at very low concentrations of tau, results in the accumulation of highmolecular weight aSyn (28, 29) . However, p-aSyn aggregates have never been observed in a transgenic tauopathy mouse model.
Here, we report hp-tau-dependent p-aSyn aggregation in a tauopathy mouse model (rTg4510) that causes overexpression of human P301L mutant tau and discuss the correlation between hp-tau and p-aSyn accumulation.
MATERIALS AND METHODS

Animals
rTg4510 mice (30), a transgenic model for human tauopathy, and control FVB/N-C57BL/6J mice were used in the study. The animals were maintained in an experimental facility at the University of Tokyo. rTg4510 mice overexpress human tau that contains the frontotemporal dementia-associated P301L mutation; tau expression can be suppressed by doxycycline treatment (30) . For the expression of mutant tau in rTg4510 mice, the mutated gene, which is located downstream of a tetracycline-operon-responsive element, must be coexpressed with an activator transgene, which consists of the tet-off open reading frame located downstream of the Ca 2þ -calmodulin kinase II promoter elements (30) . Wild-type control mice lack both the tau responder and the activator transgene. Mice under 3 months of age were housed in a cage with free access to a standard purified rodent growth diet (AIN-93G, Oriental Yeast, Tokyo, Japan), and those over 3 months of age were housed with free access to a maintenance diet (AIN-93M, Oriental Yeast). The mice were killed at 3, 6, 8.5, and 10 months of age, and the brains were collected. The institutional animal care and use committee of the Graduate School of Agricultural and Life Science at the University of Tokyo approved all experiments (Approval No. P17-020).
Histopathology
Brain tissue samples from the cerebrum and cerebellum were fixed in 10% neutral-buffered formalin, processed routinely, and embedded in paraffin wax. Formalin-fixed and paraffin-embedded tissues were cut into 2-or 6-lm thick serial sections. The deparaffinized sections were then stained with hematoxylin and eosin.
Immunohistochemistry
Consecutive sections were stained using an immunoenzyme technique. After deparaffinization and rehydration, antigen retrieval was performed via heating in order to detect hptau, NeuN, GFAP, and Iba-1. Formic acid treatment was used to detect p-aSyn. To deactivate endogenous peroxidase, the sections were immersed in 1% hydrogen peroxide in methanol for 5 minutes. To avoid nonspecific binding of the antibody, the sections were immersed in 8% skim milk in Tris-buffered saline (TBS). The following primary antibodies were used: mouse anti-hp-tau (clone AT8, 1:500, Thermo Scientific, Rockford, IL), mouse anti-NeuN (clone MAB377, 1:200, Millipore, Temecula, CA), rabbit anti-GFAP (1:1000, DAKO, Glostrup, Denmark), rabbit anti-Iba-1 (1:500, WAKO, Osaka, Japan), and mouse anti-paSyn (clone 81 A, 1:500, Abcam, Cambridge, UK). After incubation with each primary antibody at 4 C overnight, immunolabeled antigens were visualized using the Dako EnVisionþ System (Dako) with 0.01% 3 0 3-diaminobenzidine plus 0.01% hydrogen peroxide as a chromogen. To evaluate hp-tau deposition and activation of astrocytes and microglia, the percentages of hp-tau-, GFAP-, and Iba-1-positive areas were quantified using ImageJ software (National Institutes of Health, Bethesda, MD). To evaluate p-aSyn deposition and neuronal loss, the number of p-aSyn-positive cells and NeuN-positive cells were counted, respectively.
Double-Labeling Fluorescence Assay
To detect the spatial and temporal deposition of p-aSyn, we performed double-labeling immunofluorescence. After incubation with each of the primary antibodies at 4 C overnight, the sections were washed with TBS, incubated with a corresponding secondary antibody at 37 C for 1 hour, and then mounted with Vectashield (H-1500, Vector Laboratories, Burlingame, CA). The following primary antibodies were used: mouse anti-hp-tau (clone AT8, 1:100), mouse anti-p-aSyn (clone 81 A, 1:100), mouse anti-MAP2 (1:100, Millipore), rabbit anti-GFAP (1:400), rabbit anti-Olig2 (1:100, Millipore), rabbit anti-p-aSyn (clone EP1536Y, 1:100, Abcam), and mouse anti-ubiquitin (clone 10C2-2, 1:30, Abcam). The following secondary antibodies were used: Alexa Fluor 594-conjugated goat anti-mouse IgG (1:100, Invitrogen, Eugene, OR), Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:100, Life Technologies, Eugene, OR), Alexa Fluor 594-conjugated goat anti-rabbit IgG (1:100, Life Technologies), and Alexa Fluor 488-conjugated goat anti-mouse IgG (1:100, Invitrogen).
To assess the biochemical character of p-aSyn aggregates, we performed double staining for p-aSyn and Congo red. After incubation with rabbit anti-p-aSyn antibody (clone EP1536Y, 1:100) at 4 C overnight, the sections were washed with TBS, incubated with secondary antibody, Alexa Fluor 488-conjugated goat anti-rabbit IgG (1:100), at 37 C for 1 hour. The sections were then incubated in 1% Congo red solution for 10 minutes and washed in a saturated lithium carbonate solution. To break nonspecific bonds, the sections were incubated in 80% ethanol for 2 minutes, washed in TBS for 1 minute, then mounted with Vectashield (H-1500, Vector Laboratories).
The fluorescent reaction products were optimally visualized using an argon-ion laser in a Carl Zeiss LSM700 Confocal Laser Scanning Microscope (Carl Zeiss, Tokyo, Japan).
Protein Extraction
For tau and aSyn extraction, tissue samples from the hippocampus were homogenized in 7.5 volumes of TBS buffer containing 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EGTA, and 1 mM EDTA using a multi-bead shocker (Yasui Kikai, Osaka, Japan). After centrifugation at 23 000 rpm at 4 C for 15 minutes, the supernatants were collected as TBS-soluble fractions.
Western Blotting
The protein samples were dissolved in Laemmli Sample Buffer, which included 2-mercaptoethanol, and boiled for 10 minutes. The proteins dissolved in Laemmli Sample Buffer were separated using a 5%-20% gradient polyacrylamide gel (ATTO, Tokyo, Japan) or an 8% polyacrylamide gel (Nakalai Tesque, Kyoto, Japan), and then transferred to a 0.20-lm thick nitrocellulose membrane (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Nonspecific binding was blocked by treatment with Bullet Blocking One (Nakalai Tesque) for 10 minutes. The membranes were probed with the following antibodies at 4 C overnight: rabbit anti-p-aSyn (clone EP1536Y, 1:500), mouse anti-tau (1:5000, produced by A. Takashima's laboratory), and mouse anti-GAPDH (clone GT239, 1:3000, Gene Tex, Irvine, CA). After washing the membranes with TBS containing Tween 20, horseradish peroxidase (HRP)-conjugated sheep anti-rabbit IgG antibody (1:5000, GE Healthcare UK, Little Chalfont, UK) or HRPconjugated sheep anti-mouse IgG antibody (1:5000 GE Healthcare UK) was applied. Blots were developed using ECL Prime Western Blotting Detection Reagent (GE Healthcare Bio-Sciences AB). Immunoreactive bands were detected using the ChemiDoc XRSþ System (Bio-Rad Laboratories, Hercules, CA) or the Amersham Imager 600 (Bio-Rad Laboratories). 
Statistical Analysis
Data are shown as the mean 6 SD. Comparisons of the means between the rTg4510 and control mice were performed using 1-way analysis of variance followed by Tukey's multiple comparison tests. The correlation between the amounts of hp-tau and p-aSyn deposits was examined using Spearman's rank correlation. A p value <0.05 was considered significant.
RESULTS
Hp-Tau and p-aSyn Deposition in rTg4510 Mice rTg4510 mice developed hp-tau aggregates in the neuronal cytoplasm and neurites of the hippocampal CA1 and CA3 areas, dentate gyrus, motor area, somatosensory area, entorhinal cortex, piriform cortex, and amygdala ( Supplementary  Data Fig. S1A ). The mice also developed p-aSyn-positive grains, and occasionally developed p-aSyn-positive spherical LB-like inclusions and minute, uniform neuronal granules (Fig. 1A-C) . However, there were no hp-tau or p-aSyn aggregates in the brain of control mice (n ¼ 10 for 3-, 6-, 8.5-, and 10-month-old mice, Fig. 1D ). P-aSyn-positive aggregates were found in the hippocampal CA1 and CA3 areas, dentate gyrus, motor area, somatosensory area, entorhinal cortex, piriform cortex, and amygdala ( Fig. 1E-L) , which corresponded to the distribution of hp-tau aggregates. The anti-p-aSyn antibody did not recognize hp-tau in Western blotting (Supplementary Data Fig. S2A, B) . The rTg4510 mice had a significantly lower number of NeuN-positive neuronal cells ( Fig. 2A) and significantly higher percentages of GFAPpositivity (Fig. 2B) and Iba-1-positivitiy (Fig. 2C) in the hippocampal CA1 area, motor area, and entorhinal cortex than the control mice.
Spatial or Temporal Deposition of p-aSyn in rTg4510 Mice
Double-labeling immunofluorescence analysis revealed that hp-tau aggregates were found mainly in MAP2-positive neuronal cells (Supplementary Data Fig. S1B ), but not in GFAP-positive astrocytes (Supplementary Data Fig. S1C ). Hp-tau aggregates were also found in some Olig2-positive oligodendrocytes (Supplementary Data Fig. S1D ). P-aSyn aggregates were found in MAP2-positive neuronal cells (Fig. 3A) , but not in GFAP-positive astrocytes (Fig. 3B) or Olig2-positive oligodendrocytes (Fig. 3C) . Hp-tau aggregates and all morphological variants of p-aSyn aggregates were detected within the same regions. Moreover, p-aSyn aggregates were observed only in cells with hp-tau aggregates. We found numerous hp-tau-positive p-aSyn-positive cells and hp-taupositive p-aSyn-negative cells, but no hp-tau-negative p-aSyn-positive cells (Fig. 3D-F) . Furthermore, most of the p-aSyn-positive grains and p-aSyn-positive spherical LB-like inclusions did not colocalize with hp-tau aggregates, but some of these aggregates colocalized with hp-tau aggregates (Fig. 3D, E) . P-aSyn-positive minute, uniform neuronal granules often colocalized with hp-tau aggregates (Fig. 3F) . P-aSyn aggregates did not colocalize with ubiquitin and were not positive for Congo red stain (Supplementary Data Fig.  S3A-D) .
Distribution of hp-tau and p-aSyn
To evaluate the correlation between the distribution of hp-tau and p-aSyn, we determined the amount of hp-tau and p-aSyn accumulation using immunohistochemistry in 6-month-old rTg4510 mice in 10 regions: the hippocampal CA1 and CA3 areas, dentate gyrus, motor area, somatosensory area, entorhinal cortex, piriform cortex, amygdala, striatum, and substantia nigra. Numerous p-aSyn aggregates were found in the hippocampal CA1 area, motor area, entorhinal cortex, piriform cortex, and amygdala, where hp-tau accumulation was severe. However, in the dentate gyrus, striatum, and substantia nigra, where only few hp-tau inclusions were observed, p-aSyn aggregates were scarce (Fig. 4A, B) . As shown in the scatterplots (Fig. 4C, D) , there was a significant positive correlation between hp-tau and paSyn accumulation (r ¼ 0.76, p < 0.01) and between the average amounts of hp-tau and p-aSyn accumulation in each region (r ¼ 0.87, p < 0.01).
Furthermore, age-related hp-tau and p-aSyn accumulation was examined in 6 regions: the hippocampal CA1 and CA3 areas, motor area, piriform cortex, entorhinal cortex, and amygdala of 3-, 6-, 8.5-, and 10-month-old rTg4510 mice. In the brain areas studied in rTg4510 mice, agerelated increases in the amounts of hp-tau (Supplementary Data Fig. S4A-F) and p-aSyn (Supplementary Data Fig.  S4G-L) were observed. Interestingly, there were significant correlations between the amounts of hp-tau and p-aSyn accumulation in all areas (hippocampal CA1, r ¼ 0.54, p < 0.01; hippocampal CA3, r ¼ 0.84, p < 0.01; motor cortex, r ¼ 0.60, p < 0.01; entorhinal cortex, r ¼ 0.62, p < 0.01; piriform cortex, r ¼ 0.63, p < 0.01; amygdala, r ¼ 0.84, p < 0.01) (Fig. 5A-F) . Accumulation of p-aSyn in the hippocampal CA1 and CA3 areas, entorhinal cortex, and amygdala (Fig. 5G, H , J, L) was more severe than in the motor area and piriform cortex (Fig. 5I, K) .
DISCUSSION
In this study, we found that rTg4510 mice develop not only hp-tau aggregates, but also p-aSyn aggregates, in their brains. It has been reported that tau accumulation, even at very low concentration, results in the coaccumulation of aSyn polymers in vitro (28) . Overexpression of hp-tau increases the number of aSyn aggregates and the level of high-molecular weight species of aSyn; hp-tau also enhances aSyn toxicity in cultured cells (29) . The aggregation of aSyn is also found in DLB-AD transgenic mice, which express human mutant APP, PSEN1, tau (P301L), and aSyn (A53T) (31) , and in bigenic mice that express wild-type human aSyn and mutant tau (P301L) (28) . In fact, p-aSyn aggregates have never been identified in a tauopathy mouse model lacking human aSyn transgenes, though p-aSyn aggregates have been identified in lentiviral gene-transferred rats that express human wild type or mutant tau (P301L) (32) . In the present study, due to the overexpression of mutated human tau and the deposition of hp-tau, endogenous mouse aSyn was phosphorylated and accumulated in the same neuronal cells in which hp-tau accumulated. Thus, our present results support the hypothesis that hp-tau may enhance aSyn phosphorylation and accumulation in rTg4510 mice. Granular deposits of p-aSyn were frequently observed in the brain of rTg4510 mice, while spherical LB-like inclusions were rare. The morphological diversity of aSyn aggregates has previously been found in a mouse model of PD that overexpresses human mutant aSyn. Namely, E46K mutant aSyn transgenic mice develop LB-like spherical inclusions (33) , but A53T and A30P mutant aSyn transgenic mice develop a diffuse neuronal distribution of aSyn (34, 35) . In the A53T mutant aSyn transgenic mice, p-aSyn aggregates are composed mainly of human aSyn with some mouse aSyn (36) . However, in the present study using rTg4510 mice, the p-aSyn aggregates were composed only of mouse aSyn. Taken together, these data suggest that the morphological variations of p-aSyn aggregates may be due to species differences of the aSyn protein and/or intracytoplasmic environments.
Significant positive correlations between hp-tau and p-aSyn accumulation were detected in all regions studied. However, p-aSyn aggregates were not observed in areas where hp-tau aggregates were scarce, such as the substantia nigra and striatum, though numerous aSyn aggregates are known to be present in these areas in PD patients (37) . This result suggests that the aSyn protein is phosphorylated together with tau protein in rTg4510 mice. Phosphorylation of tau and aSyn are controlled by several kinases and phosphatases (1, 38, 39) . Glycogen synthase kinase-3b (GSK-3b) and protein phosphatase-2A (PP2A) are involved in the phosphorylation processes of both tau and aSyn (1, 39, 40) . Postmortem studies of AD and PD brains have revealed an overactivation of GSK3b and inactivation of PP2A (40) (41) (42) . Interestingly, the level of polo-like kinase-2 (PLK-2), a major phosphorylation enzyme for aSyn, but not for tau, is increased in AD (43) . It has also been reported that GSK-3b overactivation leads to severe hp-tau and p-aSyn accumulation in mice (44, 45) . In addition, lentiviral overexpression of wild type or P301L mutant tau leads to activation of GSK-3b and PLK-2 and inactivation of PP2A (32) . Based on these research results, it is possible that tau hyperphosphorylation activates various kinases, such as GSK-3b and PLK-2, and inactivates phosphatases such as PP2A, and that these events enhance the phosphorylation of aSyn. Moreover, the hippocampal CA1 and CA3 areas, entorhinal cortex and amygdala, where numerous LBs are found in AD (14, 17) were more prone to p-aSyn accumulation than the motor area and piriform cortex. Therefore, it is possible that the distribution of p-aSyn accumulation depends on the region-specific intracytoplasmic environment controlling the homeostasis of aSyn phosphorylation and degradation.
Under normal conditions, aSyn molecules are unfolded soluble monomers or tetramers (46, 47) , but in a-synucleinopathies these molecules are phosphorylated, tend to fold and form "oligomers", and through "protofibrils" become "mature fibrils", the main component of LBs (48, 49) . It is also known that the phosphorylation of aSyn leads to a toxic oligomeric form (50) and is the major underlying process for the formation of LBs (7) . In this study, we confirmed the deposition of endogenous p-aSyn in the brain of human tau-transgene rTg4510 mice. Previous studies (11, 27, 28, 33, (51) (52) (53) have suggested that aSyn oligomers and protofibrils lead tau molecules to hyperphosphorylation and aggregation by inhibiting the formation of tau-mediated microtubule assembly or by reducing GSK-3b activity, though the precise mechanism for this is yet to be elucidated. In this study, we confirmed that endogenous mouse aSyn phosphorylation and accumulation are accelerated when human mutant tau is overexpressed. Therefore, it is possible that the phosphorylation processes of tau and aSyn affect one another, and that this synergic effect exacerbates the pathology of neurodegenerative disorders that show a cooccurrence of hp-tau and p-aSyn accumulation.
